Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
暂无分享,去创建一个
[1] Inge Christoffer Olsen,et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.
[2] A. Ido,et al. Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel diseases , 2017, Alimentary pharmacology & therapeutics.
[3] D. D. de Jong,et al. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. , 2016, Journal of Crohn's & colitis.
[4] L. Dieleman,et al. Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes: A Retrospective Cohort Study , 2016, Inflammatory bowel diseases.
[5] N. Narula,et al. Systematic review with meta‐analysis: mucosal healing is associated with improved long‐term outcomes in Crohn's disease , 2016, Alimentary pharmacology & therapeutics.
[6] Christopher McCabe,et al. Cost Effectiveness Modelling for Health Technology Assessment , 2015 .
[7] T. Connelly,et al. Predictors of recurrence of Crohn's disease after ileocolectomy: a review. , 2014, World journal of gastroenterology.
[8] Alka B. Patel,et al. Postoperative Complications and Emergent Readmission in Children and Adults with Inflammatory Bowel Disease Who Undergo Intestinal Resection: A Population-based Study , 2014, Inflammatory bowel diseases.
[9] G. Corazza,et al. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn’s disease , 2013, The European Journal of Health Economics.
[10] J. Mate,et al. Intensification of infliximab therapy in Crohn's disease: efficacy and safety. , 2012, Journal of Crohn's & colitis.
[11] L. Peyrin-Biroulet,et al. Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.
[12] J. Gisbert,et al. Long-term Durability of Infliximab Treatment in Crohn's Disease and Efficacy of Dose “Escalation” in Patients Losing Response , 2011, Journal of clinical gastroenterology.
[13] W. Blonski,et al. What is the optimal therapy for Crohn’s disease: step-up or top-down? , 2010, Expert review of gastroenterology & hepatology.
[14] P. Rutgeerts,et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. , 2010, Gastroenterology.
[15] L. Peyrin-Biroulet,et al. Early Crohn disease: a proposed definition for use in disease-modification trials , 2010, Gut.
[16] S. Devlin,et al. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. , 2010, The Medical clinics of North America.
[17] S. Ng,et al. Clinical and surgical recurrence of Crohn's disease after ileocolonic resection in a specialist unit , 2009, European journal of gastroenterology & hepatology.
[18] C. Porter,et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. , 2008, Gastroenterology.
[19] C. Fiocchi,et al. Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. , 2008, Journal of Crohn's & colitis.
[20] N. Hyman,et al. Death after Bowel Resection: Patient Disease, Not Surgeon Error , 2008, Journal of Gastrointestinal Surgery.
[21] M. Regueiro,et al. Infliximab dose intensification in Crohn's disease , 2007, Inflammatory bowel diseases.
[22] P. Rutgeerts,et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.
[23] C. Bernstein,et al. Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study , 2006, The American Journal of Gastroenterology.
[24] S. Hanauer,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[25] O Bernell,et al. Risk factors for surgery and postoperative recurrence in Crohn's disease. , 2000, Annals of surgery.
[26] B. Feagan,et al. An Evaluation of Utility Measurement in Crohn's Disease , 1997, Inflammatory bowel diseases.
[27] Guidelines for the Economic Evaluation of Health Technologies in Ireland 2014 , 2022 .